AnySelected

Philips Healthcare is pioneering a new era in cardiovascular care with the launch of the RADIQAL study, a landmark initiative designed to gather real-world evidence supporting its innovative ultra-low X-ray dose technology. This technology promises to significantly reduce radiation exposure for both patients and medical staff during coronary procedures, without compromising the crucial diagnostic image quality.

The Challenge of Radiation Exposure in Cardiology

Coronary angiography, a vital diagnostic tool for assessing heart health, traditionally involves exposure to X-rays. While essential for accurate diagnosis and treatment planning, repeated or prolonged exposure to radiation carries potential long-term health risks. Minimising this exposure has been a key focus for healthcare professionals and medical device manufacturers alike.

Introducing Philips' Ultra-Low Dose Technology

Philips has developed a groundbreaking technology that drastically reduces the required X-ray dose while maintaining exceptional image clarity. This advancement is particularly significant when utilising diluted contrast media – a technique increasingly employed in ultra-low contrast procedures. The technology leverages advanced image processing and sophisticated algorithms to enhance image quality even with minimal radiation input.

The RADIQAL Study: Real-World Validation

The RADIQAL (Reducing Angiographic Dose with Image Quality Assessment) study is a pivotal step in validating the clinical benefits of this technology. This prospective, real-world study will involve multiple leading hospitals across Australia and New Zealand. It aims to rigorously evaluate whether Philips’ ultra-low dose technology can effectively reduce radiation exposure without impacting the quality of coronary procedures, including:

• Image Quality Assessment: Detailed analysis of angiogram quality to ensure diagnostic accuracy.
• Radiation Dose Reduction: Quantifying the reduction in X-ray exposure achieved with the new technology.
• Clinical Outcomes: Monitoring patient outcomes to assess the overall impact on clinical decision-making and treatment effectiveness.

Benefits for Patients and Healthcare Professionals

The potential benefits of this technology are far-reaching. For patients, it means reduced exposure to radiation, minimising long-term health risks associated with repeated procedures. For healthcare professionals, it creates a safer working environment, lessening their cumulative radiation exposure. Furthermore, the maintenance of high image quality ensures accurate diagnoses and effective treatment planning.

Looking Ahead

The RADIQAL study represents a significant investment by Philips in advancing cardiovascular care and improving patient safety. The results of this study are eagerly anticipated and are expected to inform clinical practice and contribute to a more sustainable and patient-centric approach to coronary procedures. Philips’ commitment to innovation continues to drive advancements that benefit both patients and the healthcare community.